Synthesis of Novel Restricted Diamines; 2-(1 -Aminocycloalkan-1-YL)ethylamines
作者:Takeshi Suzuki、Naoki Imanishi、Hirotsune Itahana、Susumu Watanuki、Mitsuaki Ohta、Toshiyasu Mase
DOI:10.1080/00397919808005943
日期:1998.2
Abstract Novel restricted diamines, 2-(1-aminocycloalkan-1-yl)ethylamines 1, were prepared by using Michael addition of ethyl cyclohexylideneacetate 2 and cycloalkylideneacetonitriles 7 with amines. In Michael addition, ester 2 needed high reaction temperature and gave several products, whereas 7 reacted smoothly and gave 2-(1-amino-1-cyclohexyl)acetonitriles 8 in good yield (NH3 85%, MeNH2 89% EtNH2
The compound 2,3-diphenyl-5-ethyl-pyrazine, useful as a precursor in the synthesis of those compounds of the class of pyrazine, arylpyrazine, diphenylpyrazine, and cycloalkylpyrazine malonates, acetates, acetamides, and acetic acids, useful for their ultraviolet light absorption properties.
FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
申请人:Ahmed Gulzar
公开号:US20090221555A1
公开(公告)日:2009-09-03
The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, A
1
, A
2
, A
3
, A
4
, and A
5
, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
申请人:Ahmed Gulzar
公开号:US20120165519A1
公开(公告)日:2012-06-28
The present invention provides a compound of formula I or II
or a pharmaceutically acceptable salt form thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, A
1
, A
2
, A
3
, A
4
, and A
5
, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors
申请人:Ahmed Gulzar
公开号:US08552186B2
公开(公告)日:2013-10-08
The present invention provides a compound of formula I or II
or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.